Aandeel SHJB.F SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Shanghai Junshi Biosciences Co., Ltd. OTC Markets

Aandelen

SHJB.F

CNE100003FF7

Beurs gesloten - OTC Markets
Andere beurzen
 14:51:46 20-03-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
1,86 USD -9,71% Intraday-grafiek van Shanghai Junshi Biosciences Co., Ltd. -.--% -13,49%
13/06 Junshi Biosciences' geneesmiddel tegen kanker krijgt registratiecertificaat van Chinese toezichthouder MT
12/06 Shanghai Junshi Biosciences Co. Ontvangt Registratiecertificaat voor Geneesmiddelen afgegeven door de National Medical Products Administration CI

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Junshi Biosciences' Cancer Drug Gets Registration Certificate from Chinese Regulator
Shanghai Junshi Biosciences Co., Ltd. Receives Drug Registration Certificate Issued by the National Medical Products Administration
Junshi Bio Achieves Primary Endpoints in Phase 3 Trial of Liver Cancer Treatment
Shanghai Junshi Biosciences Cancer Drug Shows Positive Phase III Trial Results
Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint
Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma
Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Shanghai Junshi Biosciences Receives Hong Kong Approval for Cancer Drug Toripalimab
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region
Shanghai Junshi Biosciences Co., Ltd. Announces Executive Changes
Junshi Biosciences Gets Nod to Register Toripalimab Injection
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
Shanghai Junshi Biosciences Supplemental NDA for Lipid Drug Accepted by NMPA
Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection
Tranche Update on Shanghai Junshi Biosciences Co., Ltd.'s Equity Buyback Plan announced on September 10, 2023.
Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates
Shanghai Junshi Biosciences' Loss Narrows in 2023, Misses Estimates
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers 1877
  4. Koers SHJB.F
  5. Nieuws Shanghai Junshi Biosciences Co., Ltd.
  6. Andere talen